Elisabet Selga Coma
Coordinator of the Determinants of Arrhythmogenesis Research Line
Email: elisabet.selga@umedicina.cat
ORCID: 0000-0002-4290-8370
Scientific Profile: URECERCA
Elisabet Selga is an associate professor at the Faculty of Medicine of the Universitat de Vic – Universitat Central de Catalunya.
Dr. Selga is a biologist (2004, UdG) and developed her Ph.D. on the identification of genomic nodes involved in the response to chemotherapeutic treatment with methotrexate (2009, UB). Then she moved to IDIBGI, and under a postdoctoral Sara Borrell fellowship (2012 – 2014), Dr. Selga investigated the pathophysiological effects of genetic variants in cardiac ion channels identified in patients with inherited cardiac disorders and in cases of unexplained sudden death. Her international research stay (2013 – 2014) at the prestigious MRC Centre for Regenerative Medicine in Edinburgh allowed her to implement patient-specific induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) as a cellular model to assess pathophysiological mechanisms and pharmacological responses in patients with Brugada syndrome.
In 2018 she moved to UVic-UCC as professor, and joined IRIS-CC. Since then, her research interests are I) to uncover the cardiac and neurological risk factors that lead to sudden cardiac death, and II) to quantify the impact of a holistic cardiac rehabilitation program on clinical and biochemical biomarkers, on the microbiome and on the mechanisms of atrial inflammation in patients diagnosed with atrial fibrillation and overweight/obesity.
My last happenings:
Exploiting Hormesis for Plasma-treated Hydrogel Therapeutic platforms (HormeTic)
Subprojects: Subproject 1: "Exploiting Hormesis for plasma-treated hydrogel therapeutic platforms for cancer treatment (HormOnc)". Subproject 2: "Exploiting Hormesis for plasma-treated hydrogel therapeutic platforms for Healing of complex cutaneous wounds (HormHeal)". Original Title (English): Exploiting Hormesis for plasma-treated hydrogel therapeutic platforms for Healing of complex cutaneous wounds (HormHeal). Objective: Innovating in the healing of complex wounds. TR2Lab research team members: Albert Espona-Noguera (Principal Investigator). Cristina Canal (PI1 of Subproject 1) & Francesco Tampieri (PI2 of Subproject 1). Members of TR2Lab who participate in this project: Elisabet Sarri, Laia Bosch, Gemma Sangüesa, Francesc Sant Masoliver, Cristina Martin Mancera, David Benito Guasch, Clara Masó [...]
Lactic acid as a marker of therapeutic response
Members: Dr M. Parera (CHV), Dr I. Barba (Medicina UVic) Financial support: APR-IRIS-CC The Project “Lactic acid as a marker of therapeutic response” has received approval from the IRIS-CC ethics committee and will start recruiting patients in earnest. The project is a collaboration between Consorci Hospitalari de Vic (Dr M. Parera) and the faculty of medicine UVic (Dr I.Barba) and will evaluate lactic acid as a potential marker of therapeutic response in non-small cell lung cancer patients. We would like to thank all the patients who selflessly participate in this project. El projecte «L'àcid làctic com a [...]
Predictors of Recurrence and Survival in Endometrial Cancer: A 22-Year Single-Center Cohort Study
Funding: Industrial Doctorates Plan of the Government of Catalonia (Industrial Doctorate; DI-2024-00104) Osona Contra el Càncer (OCC) «Ajuts per a Projectes de Recerca Interns» call of the Fundació d’Estudis Superiors en Ciències de la Salut (FESS; APR-2025-FESS) Authors: E. Sardo (1,6,7,8,), M. Alejo Sánchez (2,7), M. Parera Roig (1,6,7,8,), C. Cruz Zambrano (6,7,8,), N. Espejo Herrera (2,8), K. Salas León (2), A. Canet Gómez (2), M. Armengou Ríos (2), C. Vila Díaz (2), E. Puigoriol Juvanteny (3), S. Moros Weakner (4), V. Álvarez Torrecillas (4), I. Gallego Anton (8), M.Panadès Tejero (8), M. Zarcero Estevez (5), S. Griñó [...]
